ArticleFrontiers in medicine2026
Reed-Sternberg cells express CD161 and lectin-like transcript 1 in Hodgkin lymphoma.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CD161 and LLT1 expression in immune cell populations of Hodgkin lymphoma tumor microenvironment.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hodgkin lymphoma (HL) is a B-cell lymphoma, and it is diagnosed by the presence of Reed-Sternberg (RS) cells surrounded by heavy immune cell infiltration in a tissue biopsy. CD161 (Cluster of differentiation 161) and its ligand Lectin-like transcript 1 (LLT1) have recently emerged as a novel immune-regulatory axis that modulates natural killer (NK) and T cell-mediated function in cancer and inflammatory conditions, but their expression in RS cells and association with HL patients' clinical-pathological features remain poorly defined. Methods: In this study, 60 formalin-fixed paraffin-embedded (FFPE) tissue samples were collected from patients in Northern Jordan. In addition to 60 FFPE samples of positive control from benign reactive lymph node tissues and tonsils. Immunohistochemistry (IHC) was performed to assess the expression levels and patterns (cytoplasmic, membranous, or both) of CD161 and LLT1 in RS cells and then correlated with EBV status and clinical-pathological features such as subtype and disease stages. Results: LLT1 expression in RS cells was predominantly cytoplasmic, with occasional dual cytoplasmic and membranous expressions. This is the first study in the literature to detect CD161 expression in RS cells as neoplastic cells at protein level. Statistical analyses showed no significant association between LLT1 or CD161 expression in RS cells and HL subtype, stage or EBV status. Discussion: These findings provide the first characterization of LLT1 and CD161 expression in RS cells and suggest their potential use as a target in immunotherapy approaches in HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.